BLOOD CONTENT OF MATRIX METALLOPROTEINASE 9 IN PATIENTS WITH COVID-19- ASSOCIATED LUNG DISEASE

Abstract

The aim of the research. To identify the relationship between the serum content of MPP-9 and the polymorphism of the MPP-9 gene (A8202G) with the severity of the course of COVID-19-associated lung damage.Materials and methods. The paper presents the results of a survey of 200 people 1 month after suffering COVID-associated lung damage in the period from June 01 to October 31, 2020. The patients were divided into groups of 50 people depending on the degree of lung damage according to the results of computed tomography: 1st group (CT-1), 2nd group (CT-2), 3rd group (CT-3), 4th group (CT-4). The following diseases were registered in the structure of background pathology: arterial hypertension (AH), coronary heart disease (CHD), obesity, type 2 diabetes mellitus (type 2 diabetes), chronic kidney disease (CKD), COPD and bronchial asthma. The control group included 56 relatively healthy individuals who did not suffer from coronavirus infection, the median age was 55.0 [51.1; 55.0]. All groups were comparable in age and gender. The content of MMP-9 in the blood serum was studied. A molecular genetic study of the MMP-9 (A8202G) gene was also conducted.Results. As a result of the work, a lower content of MPP-9 was revealed in the control group compared to the study groups. A higher level of matrix metalloproteinase 9 was also revealed in patients with more severe COVID-19-associated lung damage (CT-4), compared to less severe patients (CT-1).Conclusion. Thus, taking into account the data obtained in patients after coronavirus infection with COVID19-associated lung damage, it can be assumed that an increased concentration of MPP-9 is one of the factors contributing to both lung damage against the background of infection and a factor in the severe course of this complication.